Effects of 5-fluorouracil adjuvant treatment of colon cancer

References

• Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002, CA Cancer J. Clin.55, 74–108 (2005).
   PubMed Web of Science ®Google Scholar
• Byers T, Gorsky R. Estimates of costs and effects of screening for colorectal cancer in the United States. Cancer70, 1288–1295 (1992).
   PubMedGoogle Scholar
• Morikawa T, Kato J, Yamaji Y, Wada R, Mitsushima T, Shiratori Y. A comparison of the immunochemical fecal occult blood test and total colonoscopy in the asymptomatic population. Gastroenterology129, 422–428 (2005).
   PubMed Web of Science ®Google Scholar
• Ribic CM, Sargent DJ, Moore MJ et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N. Engl. J. Med.349, 247–257 (2003).
   PubMed Web of Science ®Google Scholar
• Westra JL, Plukker JT, Buys CH, Hofstra RM. Genetic alterations in locally advanced Stage II/III colon cancer: a search for prognostic markers. Clin. Colorectal Cancer4, 252–259 (2004).
   PubMedGoogle Scholar
• Kornmann M, Schwabe W, Sander S et al. Thymidylate synthase and dihydropyrimidine dehydrogenase mRNA expression levels: predictors for survival in colorectal cancer patients receiving adjuvant 5-fluorouracil. Clin. Cancer Res.9, 4116–4124 (2003).
   PubMed Web of Science ®Google Scholar
• Hermanek P. pTNM and residual tumor classifications: problems of assessment and prognostic significance. World J. Surg.19, 184–190 (1995).
   PubMedGoogle Scholar
• Cucino C, Buchner AM, Sonnenberg A. Continued rightward shift of colorectal cancer. Dis. Colon Rectum45, 1035–1040 (2002).
   PubMedGoogle Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N. Engl. J. Med.322, 352–358 (1990).
   PubMed Web of Science ®Google Scholar
• Comparison of flourouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet355, 1588–1596 (2000).
   PubMed Web of Science ®Google Scholar
• Andre T, Boni C, Mounedji-Boudiaf L et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. Med.350, 2343–2351 (2004).
   PubMed Web of Science ®Google Scholar
• Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351, 337–345 (2004).
   PubMed Web of Science ®Google Scholar
• Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22, 23–30 (2004).
   PubMed Web of Science ®Google Scholar
• Hurwitz HI, Fehrenbacher L, Hainsworth JD et al. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer. J. Clin. Oncol.23, 3502–3508 (2005).
   PubMed Web of Science ®Google Scholar
• Link KH, Kornmann M, Staib L, Redenbacher M, Kron M, Beger HG. Increase of survival benefit in advanced resectable colon cancer by extent of adjuvant treatment: results of a randomized trial comparing modulation of 5-FU + levamisole with folinic acid or with interferon-α. Ann. Surg.242, 178–187 (2005).
   PubMedGoogle Scholar
• Martenson JA Jr, Willett CG, Sargent DJ et al. Phase III study of adjuvant chemotherapy and radiation therapy compared with chemotherapy alone in the surgical adjuvant treatment of colon cancer: results of intergroup protocol 0130. J. Clin. Oncol.22, 3277–3283 (2004).
   PubMed Web of Science ®Google Scholar
• Nordlinger B, Rougier P, Arnaud JP et al. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with Stage II–III colorectal cancer: a multicentre randomised controlled Phase III trial. Lancet Oncol.6, 459–468 (2005).
   PubMed Web of Science ®Google Scholar
• Poplin EA, Benedetti JK, Estes NC et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of Stage III and high-risk Stage II colon cancer. J. Clin. Oncol.23, 1819–1825 (2005).
   PubMed Web of Science ®Google Scholar
• Smith RE, Colangelo L, Wieand HS, Begovic M, Wolmark N. Randomized trial of adjuvant therapy in colon carcinoma: 10-year results of NSABP protocol C-01, J. Natl Cancer Inst.96, 1128–1132 (2004).
   PubMedGoogle Scholar
• Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for Stage III colon cancer. N. Engl. J. Med.352, 2696–2704 (2005).
   PubMed Web of Science ®Google Scholar
• Boland CR, Sato J, Appelman HD, Bresalier RS, Feinberg AP. Microallelotyping defines the sequence and tempo of allelic losses at tumour suppressor gene loci during colorectal cancer progression. Nat. Med.1, 902–909 (1995).
   PubMed Web of Science ®Google Scholar
• Lengauer C, Kinzler KW. Vogelstein B, Genetic instabilities in human cancers. Nature396, 643–649 (1998).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Hamilton SR et al. Genetic alterations during colorectal-tumor development. N. Engl. J. Med.319, 525–532 (1988).
   PubMed Web of Science ®Google Scholar
• Vogelstein B, Fearon ER, Kern SE et al. Allelotype of colorectal carcinomas. Science244, 207–211 (1989).
   PubMed Web of Science ®Google Scholar
• Fishel R. The selection for mismatch repair defects in hereditary nonpolyposis colorectal cancer: revising the mutator hypothesis, Cancer Res.61, 7369–7374 (2001).
   PubMedGoogle Scholar
• Gryfe R, Gallinger S. Microsatellite instability, mismatch repair deficiency, and colorectal cancer. Surgery130, 17–20 (2001).
   PubMedGoogle Scholar
• Ionov Y, Peinado MA, Malkhosyan S, Shibata D, Perucho M. Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis. Nature363, 558–561 (1993).
   PubMed Web of Science ®Google Scholar
• Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell87, 159–170 (1996).
   PubMed Web of Science ®Google Scholar
• Thibodeau SN, French AJ, Roche PC et al. Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res.56, 4836–4840 (1996).
   PubMed Web of Science ®Google Scholar
• Gryfe R, Kim H, Hsieh ET et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N. Engl. J. Med.342, 69–77 (2000).
   PubMed Web of Science ®Google Scholar
• Lothe RA, Peltomaki P, Meling GI et al. Genomic instability in colorectal cancer: relationship to clinicopathological variables and family history. Cancer Res.53, 5849–5852 (1993).
   PubMed Web of Science ®Google Scholar
• In: American Joint Committee on Cancer - Cancer staging handbook, TNM classification of malignant tumors.Greene, Batch CM, Fleming ID et al. (Eds). Springer, NY, USA (2002).
   Google Scholar
• Link KH, Sagban TA, Morschel M et al. Colon cancer: survival after curative surgery. Langenbecks Arch. Surg.390, 83–93 (2005).
   PubMed Web of Science ®Google Scholar
• Baron TH. Colonic stenting: technique, technology, and outcomes for malignant and benign disease. Gastrointest. Endosc. Clin. N. Am.15, 757–771 (2005).
   PubMedGoogle Scholar
• Andre N, Schmiegel W. Chemoradiotherapy for colorectal cancer. Gut54, 1194–1202 (2005).
   PubMed Web of Science ®Google Scholar
• Wiggers T, Jeekel J, Arends JW et al. No-touch isolation technique in colon cancer: a controlled prospective trial. Br. J. Surg.75, 409–415 (1988).
   PubMed Web of Science ®Google Scholar
• van Triest B, Pinedo HM, Giaccone G, Peters GJ. Downstream molecular determinants of response to 5-fluorouracil and antifolate thymidylate synthase inhibitors. Ann. Oncol.11, 385–391 (2000).
   PubMed Web of Science ®Google Scholar
• Laurie JA, Moertel CG, Fleming TR et al. Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J. Clin. Oncol.7, 1447–1456 (1989).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Fisher B, Rockette H et al. Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J. Natl Cancer Inst.80, 30–36 (1988).
   PubMed Web of Science ®Google Scholar
• Benson AB III, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for Stage II colon cancer, J. Clin. Oncol.22, 3408–3419 (2004).
   PubMed Web of Science ®Google Scholar
• Schippinger W, Jagoditsch M, Sorre C et al. A prospective randomised trial to study the role of levamisole and interferon α in an adjuvant therapy with 5-FU for Stage III colon cancer. Br. J. Cancer92, 1655–1662 (2005).
   PubMedGoogle Scholar
• Kerr DJ. 5-Fluorouracil and folinic acid: interesting biochemistry or effective treatment? Br. J. Cancer60, 807–808 (1989).
   PubMed Web of Science ®Google Scholar
• Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet345, 939–944 (1995).
   PubMed Web of Science ®Google Scholar
• O'Connell MJ, Laurie JA, Kahn M et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J. Clin. Oncol.16, 295–300 (1998).
   PubMed Web of Science ®Google Scholar
• Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk Stage II and III colon cancer: final report of Intergroup 0089. J. Clin. Oncol.23, 8671–8678 (2005).
   PubMed Web of Science ®Google Scholar
• Wolmark N, Wieand S, Lembersky B, Colangelo L, Smith R, Pazdur R. A Phase III trial comparing oral UFT to FULV in Stage II and II carcinoma of the colon: results of NSABP protocol c-06. Proc. Am. Soc. Clin. Oncol.23(Suppl.) 247 (2004) (Abstract 3508).
   Google Scholar
• Kelly H, Goldberg RM. Systemic therapy for metastatic colorectal cancer: current options, current evidence. J. Clin. Oncol.23, 4553–4560 (2005).
   PubMed Web of Science ®Google Scholar
• Saltz L, Niedzwiecki D, Hollis D et al. Irinotecan plus fluorouracil/leucovorin versus fluorouracil/leucovorin alone in Stage II colon cancer (intergroup trial CALGB c89803) Proc. Am. Soc. Clin. Oncol.23(Suppl.) 245 (2004) (Abstract 3500).
   Google Scholar
• Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22, 229–237 (2004).
   PubMed Web of Science ®Google Scholar
• van Cutsem E, Labianca R, Hossfeld D et al. Randomized Phase III trial comparing infused irinotecan/5-fluorouracil/folinic acid versus 5-fluorouracil/folinic acid in Stage III colon cancer patients (PETACC3). Proc. Am. Soc. Clin. Oncol.23(Suppl.) 1090 (2005).
   Google Scholar
• de Gramont A, Boni C, Navarro M et al. Oxaliplatin/5FU/LV in the adjuvant treatment of Stage II and III colon cancer: efficacy results with a median follow-up of 4 years. Proc. Am. Soc. Clin. Oncol.23(Suppl.) 246 (2005).
   Google Scholar
• Wolmark N, Wieand HS, Kuebler JP, Colangelo L, Smith R. A clinical trial comparing 5-fluorouracil (5-FU) plus leucovorin (LV) and oxaliplatin with 5-FU plus LV for the treatment of patients with Stages II and III carcinoma of the Colon. American Society Clinical Oncology Annual Meeting, FL, USA, 13–17 May 2005 (Abstract 3500).
   Google Scholar
• Arkenau H, Schmoll H, Kubicka S et al. Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal cancer: results of the safety and efficacy analysis. American Society Clinical Oncology Annual Meeting, FL, USA, 13–17 May 2005 (Abstract 3507).
   Google Scholar
• Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) investigators. J. Clin. Oncol.17, 1356–1363 (1999).
   PubMed Web of Science ®Google Scholar
• Gray R, Barnwell J, Hills R, McConkey C, Willimas N, Kerr D. QUASAR: a randomized study of adjuvant chemotherapy vs observation including 3238 colorectal cancer patients. Proc. Am. Soc. Clin. Oncol.23(Suppl.) 245 (2004) (Abstract 3501).
   Google Scholar
• Mamounas E, Wieand S, Wolmark N et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J. Clin. Oncol.17, 1349–1355 (1999).
   PubMed Web of Science ®Google Scholar
• Moertel CG, Fleming TR, Macdonald JS et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for Stage II/Dukes' B2 colon cancer. J. Clin. Oncol.13, 2936–2943 (1995).
   PubMed Web of Science ®Google Scholar
• Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in Stage II and III. Br. J. Cancer85, 1437–1443 (2001).
   PubMed Web of Science ®Google Scholar
• Simmonds PC. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group. BMJ321, 531–535 (2000).
   PubMed Web of Science ®Google Scholar
• Adam R, Avisar E, Ariche A et al. Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann. Surg. Oncol.8, 347–353 (2001).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350, 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Kabbinavar FF, Hambleton J, Mass RD, Hurwitz HI, Bergsland E, Sarkar S. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J. Clin. Oncol.23, 3706–3712 (2005).
   PubMed Web of Science ®Google Scholar
• Harris BE, Carpenter JT, Diasio RB. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Cancer68, 499–501 (1991).
   PubMed Web of Science ®Google Scholar
• Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res.53, 5433–5438 (1993).
   PubMed Web of Science ®Google Scholar
• VanKuilenburg AB, Vreken P, Beex LV et al. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Eur. J. Cancer33, 2258–2264 (1997).
   PubMedGoogle Scholar
• Diasio RB. The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology (Williston. Park), 12, 23–27 (1998).
   PubMedGoogle Scholar
• Cunningham D, Pyrhonen S, James RD et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet352, 1413–1418 (1998).
   PubMed Web of Science ®Google Scholar
• Mulder NH. New oncolytic agents and immunomodulators and their application. Ned. Tijdschr. Geneeskd.149, 1438–1440 (2005).
   PubMedGoogle Scholar
• Le Voyer T, Sigurdson ER, Hanlon AL et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed. A secondary survey of Int-0089. J. Clin. Oncol.21(15), 2912–2919 (2003).
   PubMed Web of Science ®Google Scholar
• Haboubi NY, Abdalla SA, Amini S et al. The novel combination of fat clearance and immunohistochemistry improves prediction of the outcome of patients with colorectal carcinomas: a preliminary study. Int. J. Colorectal Dis.13, 99–102 (1998).
   PubMedGoogle Scholar
• Greenson JK, Isenhart CE, Rice R, Mojzisik C, Houchens D, Martin EW Jr. Identification of occult micrometastases in pericolic lymph nodes of Duke's B colorectal cancer patients using monoclonal antibodies against cytokeratin and CC49. Correlation with long-term survival. Cancer73, 563–569 (1994).
   PubMed Web of Science ®Google Scholar
• Liefers GJ, Cleton-Jansen AM, van de Velde CJ et al. Micrometastases and survival in Stage II colorectal cancer. N. Engl. J. Med.339, 223–228 (1998).
   PubMed Web of Science ®Google Scholar
• Bilchik AJ, Nora D, Tollenaar RA, van de Velde CJ et al. Ultrastaging of early colon cancer using lymphatic mapping and molecular analysis. Eur. J. Cancer38, 977–985 (2002).
   PubMed Web of Science ®Google Scholar
• Paramo JC, Summerall J, Wilson C et al. Intraoperative sentinel lymph node mapping in patients with colon cancer. Am. J. Surg.182, 40–43 (2001).
   PubMed Web of Science ®Google Scholar
• Saha S, Bilchik A, Wiese D et al. Ultrastaging of colorectal cancer by sentinel lymph node mapping technique – a multicenter trial. Ann. Surg. Oncol.8, S94–S98 (2001).
   PubMedGoogle Scholar
• 't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature415, 530–536 (2002).
   PubMed Web of Science ®Google Scholar
• Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. Nat. Genet.33, 49–54 (2003).
   PubMed Web of Science ®Google Scholar
• van de Vijver MJ, He YD, van't Veer LJ et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med.347, 1999–2009 (2002).
   PubMed Web of Science ®Google Scholar
• Wang Y, Jatkoe T, Zhang Y et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J. Clin. Oncol.22, 1564–1571 (2004).
   PubMed Web of Science ®Google Scholar
• Lenz HJ. Pharmacogenomics and colorectal cancer. Ann. Oncol.15(Suppl. 4), iv173–iv177 (2004).
   PubMedGoogle Scholar
• Edler D, Glimelius B, Hallstrom M et al. Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracil-based chemotherapy. J. Clin. Oncol.20, 1721–1728 (2002).
   PubMed Web of Science ®Google Scholar
• Formentini A, Henne-Bruns D, Kornmann M. Thymidylate synthase expression and prognosis of patients with gastrointestinal cancers receiving adjuvant chemotherapy: a review. Langenbecks Arch. Surg.389, 405–413 (2004).
   PubMedGoogle Scholar
• Volk J, Reinke F, Van Kuilenburg AB et al. Safe administration of irinotecan, oxaliplatin and raltitrexed in a DPD-deficient patient with metastatic colon cancer. Ann. Oncol.12, 569–571 (2001).
   PubMedGoogle Scholar